CXCL12 and endothelial dysfunction: Moreover, the addition of CXCL12 to old fisetin plasma recapitulated age-related endothelial dysfunction, indicating that senolytic treatment with fisetin mitigated circulating SASP milieu-related endothelial dysfunction, in part, by targeting CXCL12.